ArticleAnnals of the New York Academy of Sciences2009
Blocking interleukin-1 in rheumatic diseases.
Article in Annals of the New York Academy of Sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 95 citations in OpenAlex.
- Maternal plasma cytokines and the subsequent risk of uterine atony and postpartum hemorrhage.Journal of perinatal medicine · 2023Article
- Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes.Frontiers in immunology · 2023Review
- Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.Medicina (Kaunas, Lithuania) · 2022Review
- Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.Immune network · 2022Review
- JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?Current rheumatology reports · 2021Review
- Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms.Journal of inflammation research · 2021Review
- Monogenic autoinflammatory diseases in children: single center experience with clinical, genetic, and imaging review.Insights into imaging · 2020Review
- Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nature reviews. Rheumatology · 2020Review
- Assessing whether the association between rheumatoid arthritis and schizophrenia is bidirectional: A nationwide population-based cohort study.Scientific reports · 2019Article
- Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review.Clinical reviews in allergy & immunology · 2018Review
- International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors.Rheumatology (Oxford, England) · 2017Article
- The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats.Neurochemical research · 2017Article
- Functions of interleukin-34 and its emerging association with rheumatoid arthritis.Immunology · 2016Review
- Autoinflammatory Skin Disorders: The Inflammasomme in Focus.Trends in molecular medicine · 2016Review
- Early detection of sensorineural hearing loss in Muckle-Wells-syndrome.Pediatric rheumatology online journal · 2015Article
- Protective and detrimental roles of inflammasomes in disease.Seminars in immunopathology · 2015Review
- IL-1 Receptor Blockade Alleviates Graft-versus-Host Disease through Downregulation of an Interleukin-1β-Dependent Glycolytic Pathway in Th17 Cells.Mediators of inflammation · 2015Article
- Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease.Mediators of inflammation · 2015Review
- Review of Systemic Immunosuppression for Autoimmune Uveitis.Ophthalmology and therapy · 2014Review
- Potent anti-inflammatory and antiproliferative effects of gambogic acid in a rat model of antigen-induced arthritis.Mediators of inflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The role of the potent proinflammatory cytokine IL-1 in disease could clinically be investigated with the development of the IL-1 blocking agent anakinra (Kineret), a recombinant IL-1 receptor antagonist. It was first tested in patients with sepsis without much benefit but was later FDA approved for the treatment of patients with rheumatoid arthritis. More recently IL-1 blocking therapies are used successfully to treat a new group of immune-mediated inflammatory conditions, autoinflammatory diseases. These conditions include rare hereditary fever syndromes and pediatric and adult conditions of Still's disease. Recently the FDA approved two additional longer acting IL-1 blocking agents, for the treatment of cryopyrin-associated periodic syndromes (CAPS), an IL-1 dependent autoinflammatory syndrome. The study of autoinflammatory diseases revealed mechanisms of IL-1 mediated organ damage and provided concepts to a better understanding of the pathogenesis of more common diseases such as gout and Type 2 diabetes which show initial promising results with IL-1 blocking therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.